Jun Nakata

Dr. Jun Nakata

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
KHKana Hasegawa
Kana Hasegawa
SIShunya Ikeda
Shunya Ikeda
MYMoto Yaga
Moto Yaga
KWKouki Watanabe
Kouki Watanabe
RURika Urakawa
Rika Urakawa
NHNaoki Hosen
Naoki Hosen
Cancer-specific cell surface antigens are ideal therapeutic targets for monoclonal antibody (mAb)–based therapy. Here, we report that multiple myeloma (MM), an incurable hematological malignancy, can be specifically targeted by an mAb that recognizes a ubiquitously present protein, CD98 heavy chain (hc) (also known as SLC3A2). We screened more than 10,000 mAb clones raised against MM cells and identified R8H283, an mAb that bound MM cells but not normal hematopoietic or nonhematopoietic cells. R8H283 specifically recognized CD98hc. R8H283 did not react with monomers of CD98hc; instead, it bound CD98hc in heterodimers with a CD98 light chain (CD98lc), a complex that functions as an amino acid transporter. CD98 heterodimers were abundant on MM cells and took up amino acids for constitutive production of immunoglobulin. Although CD98 heterodimers were also present on normal leukocytes, R8H283 did not react with them. The glycoforms of CD98hc present on normal leukocytes were distinct from those present on MM cells, which may explain the lack of R8H283 reactivity to normal leukocytes. R8H283 exerted anti-MM effects without damaging normal hematopoietic cells. These findings suggested that R8H283 is a candidate for mAb-based therapies for MM. In addition, our findings showed that a cancer-specific conformational epitope in a ubiquitous protein, which cannot be identified by transcriptome or proteome analyses, can be found by extensive screening of primary human tumor samples.

29 December 2015 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
NHNozomi Hojo
Nozomi Hojo
NTNaoya Tatsumi
Naoya Tatsumi
NMNahoko Moriguchi
Nahoko Moriguchi
AMAkihide Matsumura
Akihide Matsumura
SMSoyoko Morimoto
Soyoko Morimoto
Yusuke OjiYusuke Oji
Yusuke Oji

23 May 2017 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JNJun Nakata
Jun Nakata
YNYoshiki Nakae
Yoshiki Nakae
MKManabu Kawakami
Manabu Kawakami
SMSoyoko Morimoto
Soyoko Morimoto
DMDaisuke Motooka
Daisuke Motooka
HSHaruo Sugiyama
Haruo Sugiyama

13 November 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
JNJun Nakata
Jun Nakata
HNHiroko Nakajima
Hiroko Nakajima
HHHiromu Hayashibara
Hiromu Hayashibara
KIKanako Imafuku
Kanako Imafuku
SMSoyoko Morimoto
Soyoko Morimoto
HSHaruo Sugiyama
Haruo Sugiyama
Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides

13 December 2013 in Leukemia
Verified
Journal Article
Closed access
PDF file
JNJun Nakata
Jun Nakata
KNK Nakano
K Nakano
AOA Okumura
A Okumura
YMY Mizutani
Y Mizutani
HKH Kinoshita
H Kinoshita
NHN Hosen
N Hosen

5 June 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
JNJun Nakata
Jun Nakata
KIKayako Isohashi
Kayako Isohashi
YOYoshihiro Oka
Yoshihiro Oka
HNHiroko Nakajima
Hiroko Nakajima
SMSoyoko Morimoto
Soyoko Morimoto
HSHaruo Sugiyama
Haruo Sugiyama
Assessment of tumor response during treatment is one of the most important purposes of imaging. Before the appearance of immunotherapy, response evaluation criteria in solid tumors (RECIST) and positron emission tomography response criteria in solid tumors (PERCIST) were, respectively, the established morphologic and metabolic response criteria, and cessation of treatment was recommended when progressive disease was detected according to these criteria. However, various types of immunotherapy have been developed over the past 20 years, which show novel false positive findings on images, as well as distinct response patterns from conventional therapies. Antitumor immune response itself causes 18F-fluorodeoxyglucose (FDG) uptake in tumor sites, known as “flare phenomenon”, so that positron emission tomography using FDG can no longer accurately identify remaining tumors. Furthermore, tumors often initially increase, followed by stability or decrease resulting from immunotherapy, which is called “pseudoprogression”, so that progressive disease cannot be confirmed by computed tomography or magnetic resonance imaging at a single time point. As a result, neither RECIST nor PERCIST can accurately predict the response to immunotherapy, and therefore several new response criteria fixed for immunotherapy have been proposed. However, these criteria are still controversial, and also require months for response confirmation. The establishment of optimal response criteria and the development of new imaging technologies other than FDG are therefore urgently needed. In this review, we summarize the false positive images and the revision of response criteria for each immunotherapy, in order to avoid discontinuation of a truly effective immunotherapy.